Safinamide - Parkinson's disease
You are here : Home > Formulary Search > Safinamide - Parkinson's disease
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Safinamide
Indication :
Parkinson's disease
Group Name :
Keywords :
PD
Brand Names Include :
Xadago
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Safinamide is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Parkinson's disease.
- Amantadine hydrochloride
- Apomorphine hydrochloride
- Bromocriptine
- Cabergoline
- Clonazepam
- Co-beneldopa
- Co-careldopa
- Entacapone
- Foslevodopa with foscarbidopa
- Levodopa with carbidopa and entacapone
- Melatonin
- Opicapone
- Orphenadrine hydrochloride
- Pergolide mesilate
- Pramipexole
- Procyclidine hydrochloride
- Rasagiline mesilate
- Ropinirole hydrochloride
- Rotigotine
- Selegiline hydrochloride
- Tolcapone
- Trihexyphenidyl hydrochloride
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The Prescribing Clinical Network does not recommend Safinamide as add on therapy to Levodopa, alone or in combination to other treatments in adult patients with idiopathic Parkinson’s Disease
Safinamide will be considered BLACK on the traffic light status for all new patients as there are more cost effective treatment options available.
Patients whose treatment with safinamide was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.
Safinamide will be considered BLACK on the traffic light status for all new patients as there are more cost effective treatment options available.
Patients whose treatment with safinamide was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.